CancerCare Manitoba Research Institute, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
Department of Medicine, University of Calgary, Calgary, AB T2N 2T9, Canada.
Curr Oncol. 2021 Nov 8;28(6):4542-4551. doi: 10.3390/curroncol28060385.
Malignant pleural mesothelioma is a rare and aggressive malignancy arising from mesothelial cells that line the serous membranes of the body. Cytotoxic chemotherapy has been a mainstay of therapy, resulting in a modest improvement in overall survival, but toxicity limits the eligible patient population. Few targeted agents beyond bevacizumab have demonstrated superior efficacy compared to placebos. With an improved understanding of the relationship between the immune system and cancer progression, immunotherapies are playing a greater role in the treatment of many cancers. Several early- and late-phase trials in malignant pleural mesothelioma, including assessments of the first-line efficacy of combination ipilimumab/nivolumab treatment, have now demonstrated promising results for both immune checkpoint inhibition and cell-based therapies. These immune therapies are likely to play a central role in the treatment of this disease going forward.
恶性胸膜间皮瘤是一种罕见且侵袭性的恶性肿瘤，源于覆盖体腔浆膜的间皮细胞。细胞毒性化疗一直是治疗的主要手段，导致总生存率略有改善，但毒性限制了合格的患者人群。与安慰剂相比，贝伐珠单抗以外的靶向药物很少显示出优越的疗效。随着人们对免疫系统与癌症进展之间关系的认识不断提高，免疫疗法在许多癌症的治疗中发挥着越来越重要的作用。几项恶性胸膜间皮瘤的早期和晚期临床试验，包括对联合使用伊匹单抗/纳武单抗一线治疗疗效的评估，现已证明免疫检查点抑制和基于细胞的治疗均有前景。这些免疫疗法很可能在未来治疗这种疾病中发挥核心作用。
